We provide methodological and strategic advice for reimbursement assessment to demonstrate the value of products and gain market access. We assist the pharmaceutical and medical device companies in Health Technology Assessment (HTA) submission to secure the recommended status from national and regional health care programs. We provide critical review of existing economic models and HTA evidence materials and implements global economic models or HTA agency, specific models. All of our economic models can be adapted to reflect intra-country and regional differences.
- Methodological and strategic advice
- Preparation for formal HTA scientific advice
- Critical review of your HTA submission
- Review, critique and development of HEOR evidence generation plans (e.g. clinical trial design and outcomes assessment/instrument selection, payer evidence planning)
- Review and critique of existing economic models and HTA evidence materials